Humedix Co Ltd (200670) - Total Liabilities

Latest as of June 2026: ₩26.49 Billion KRW ≈ $17.95 Million USD

Based on the latest financial reports, Humedix Co Ltd (200670) has total liabilities worth ₩26.49 Billion KRW (≈ $17.95 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Humedix Co Ltd to see how much of total assets are deployed in long-term investments.

Humedix Co Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Humedix Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Humedix Co Ltd (200670) total assets.

Humedix Co Ltd Competitors by Total Liabilities

The table below lists competitors of Humedix Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Iron Force Industrial Co Ltd
TW:2228
Taiwan NT$1.98 Billion
SOL-GEL TECHN. IS-10
F:4SG
Germany €5.66 Million
Formosa Oilseed Processing Co Ltd
TW:1225
Taiwan NT$3.81 Billion
Rico Auto Industries Limited
NSE:RICOAUTO
India Rs-7.84 Billion
SHIPPING CORPORATION OF INDIA LAND
NSE:SCILAL
India Rs5.45 Billion
Ag Growth International Inc
TO:AFN
Canada CA$1.43 Billion
ANGI Homeservices Inc
NASDAQ:ANGI
USA $637.85 Million
Prosafe SE
OL:PRS
Norway Nkr351.70 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Humedix Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Humedix Co Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.09 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Humedix Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Humedix Co Ltd (2015–2025)

The table below shows the annual total liabilities of Humedix Co Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩24.05 Billion
≈ $16.30 Million
+13.34%
2024-12-31 ₩21.22 Billion
≈ $14.38 Million
-3.17%
2023-12-31 ₩21.91 Billion
≈ $14.85 Million
-75.10%
2022-12-31 ₩88.03 Billion
≈ $59.65 Million
-2.05%
2021-12-31 ₩89.87 Billion
≈ $60.90 Million
+61.70%
2020-12-31 ₩55.58 Billion
≈ $37.67 Million
+111.18%
2019-12-31 ₩26.32 Billion
≈ $17.84 Million
+18.86%
2018-12-31 ₩22.14 Billion
≈ $15.00 Million
+1.46%
2017-12-31 ₩21.82 Billion
≈ $14.79 Million
-1.02%
2016-12-31 ₩22.05 Billion
≈ $14.94 Million
+261.59%
2015-12-31 ₩6.10 Billion
≈ $4.13 Million
--

About Humedix Co Ltd

KQ:200670 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$188.10 Million
₩277.56 Billion KRW
Market Cap Rank
#16855 Global
#647 in Korea
Share Price
₩25000.00
Change (1 day)
-2.72%
52-Week Range
₩22600.00 - ₩66300.00
All Time High
₩75800.00
About

Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more